{
    "clinical_study": {
        "@rank": "119423", 
        "arm_group": {
            "arm_group_label": "Irinotecan, Bevacizumab and FDOPA-PET/MRI imaging", 
            "arm_group_type": "Experimental", 
            "description": "Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider."
        }, 
        "brief_summary": {
            "textblock": "To determine if FDOPA-PET/MRI imaging can predict response to treatment of  bevacizumab."
        }, 
        "brief_title": "Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors", 
        "completion_date": {
            "#text": "April 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Astrocytoma, Oligoastrocytoma, Mixed", 
            "Ganglioneuroma", 
            "Glioma", 
            "Ganglioglioma", 
            "Glioblastoma Multiforme Glioma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Astrocytoma", 
                "Ganglioneuroma", 
                "Ganglioneuroblastoma", 
                "Glioblastoma", 
                "Glioma", 
                "Central Nervous System Neoplasms", 
                "Ganglioglioma", 
                "Oligodendroglioma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Evaluate the feasibility of using FDOPA-PET/MRI pediatric patients with CNS tumors.\n      Positive results in this small study would provide the data needed to expand the study to\n      validate the use in a larger population of pediatric patients.  Validating the use of\n      FDOPA-PET imaging as an early predictor for response to anti-angiogenic therapy could\n      greatly impact the standard of care for treating and evaluating pediatric brain tumors and\n      provide a useful biomarker for assessing experimental therapeutics."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must have histological verification of one of the eligible diagnosis listed\n             below.\n\n          -  Biopsy is required at time of diagnosis, with the exception of optic pathway tumors.\n\n          -  Patients with spinal cord disease are eligible if they have a lesion >1 cm in 2\n             dimensions.\n\n        The following histologies are eligible:\n\n          -  Astrocytoma variants: fibrillary, protoplasmic, mixed\n\n          -  Pilocytic astrocytoma, including pilomyxoid variants\n\n          -  Pleomorphic xanthoastrocytoma\n\n          -  Infantile desmoplastic astrocytoma\n\n          -  Ganglioneuroma\n\n          -  Oligodenroglial tumor\n\n          -  Mixed glioma (including oligoastrocytoma)\n\n          -  Anaplastic astrocytoma\n\n          -  Anaplastic oligoastrocytoma\n\n          -  Anaplastic oligodendroglioma\n\n          -  Anaplastic ganglioglioma\n\n          -  Glioblastoma multiforme (including giant cell and gliosarcoma types)\n\n          -  Medulloblastoma\n\n          -  Ependymoma\n\n          -  Other rare malignant CNS tumors (i.e., pineal blastoma, small cell astrocytoma, etc.)\n\n               -  Patient must be \u2264 21 years of age at time of study enrollment.\n\n               -  Patient must have measurable residual disease, defined as tumor that is\n                  measurable in two perpendicular diameters on MRI.  Diffuse leptomeningeal\n                  disease is not considered measurable.\n\n               -  Patient must have a Lansky or Karnofsky performance of >40% corresponding to\n                  ECOG categories 0, 1, or 2.  Karnofsky will be used for patients >16 years of\n                  age and Lansky for patients <16 years of age.   Patients who are unable to walk\n                  because of paralysis, but who are up in a wheelchair, will be considered\n                  ambulatory for the purpose of assessing the performance score.\n\n               -  Patient must have a life expectancy of >8 weeks.\n\n               -  Patient must have fully recovered from the acute toxic effects of all prior\n                  chemotherapy or radiation prior to entering this study.\n\n               -  Patient must have recovered from any surgical procedure before enrolling on this\n                  study.\n\n               -  Hypertensive patients are eligible provided the hypertension is well controlled\n                  (95th percentile for age and height if patient \u226417 years) on stable doses of\n                  medication. (See Appendices I and II for tables of blood pressure based on age\n                  and gender).\n\n               -  Patients receiving corticosteroids are eligible provided the dose is stable or\n                  decreasing for at least 7 days.\n\n               -  Patient must have adequate bone marrow function (including status post-SCT)\n                  defined as:\n\n                    1. Peripheral absolute neutrophil count (ANC) \u22651000/uL (must not have received\n                       G-CSF within the prior 7 days)\n\n                    2. Platelet count \u2265 100,000/uL (transfusion independent)\n\n                    3. Hemoglobin \u2265 8.0 gm/dL (may receive pRBC transfusions)\n\n               -  Patient must have adequate renal function defined as:\n\n                  a. Creatinine clearance or radioisotope GFR \u226570ml/min/1.73 m2 or b. A serum\n                  creatinine based on age/gender as follows: NOTE: for MRI imaging serum\n                  creatinine measurement must meet the same criteria and be measured within 1 week\n                  of the imaging session Age                                Maximum Serum\n                  Creatinine (mg/dL) Male                      Female\n\n                  1 month to < 6 months 0.4                           0.4 6 months to < 1 year 0.5\n                                            0.5\n\n                    1. to <2 years                 0.6                           0.6\n\n                    2. to < 6 years                 0.8                           0.8\n\n                  6 to <10 years                 1.0                           1.0 10 to <13 years\n                                  1.2                           1.2 13 to <16 years\n                   1.5                           1.4\n\n                  \u226516 years                 1.7                           1.4 The threshold\n                  creatinine values in this table were derived from the Schwartz formula for\n                  estimating GFR (Schwartz et al. J.Peds 106:522, 1985) utilizing child length and\n                  stature data published by the CDC.\n\n               -  Urine protein should be screened by dipstick analysis.  If protein \u2265 2+ on\n                  dipstick, then Urine Protein Creatinine (UPC) ratio should be calculated. If UPC\n                  ratio >1, 24-hour urine protein should be obtained and the level should be <1000\n                  mg/24 hours for patient enrollment.\n\n        Note: UPC ratio of spot urine is an estimation of the 24 hour urine protein excretion- a\n        UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm.  UPC ratio is\n        calculated using of the following formulae:\n\n        [urine protein]/[urine creatinine] - if both protein and creatinine are reported in mg/dL\n        [(urine protein x 0.088]/[urine creatinine] - if urine creatinine is reported in mmol/L\n\n          -  Patient must have adequate liver function defined as:\n\n               1. Total bilirubin \u22641.5x upper limit of normal for age (ULN)\n\n               2. SGPT (ALT) \u2264 2.5 x the upper limit of normal (ULN) for age\n\n          -  Patient must have adequate coagulation defined as:\n\n             a. INR/PT <1.5 x upper limits of normal\n\n          -  Patients with a seizure disorder are eligible if well-controlled on anticonvulsants.\n             If on a non-enzyme inducing anticonvulsant, the irinotecan dose will be adjusted as\n             outline in treatment plan.\n\n          -  Sexually active patients of childbearing potential must agree to use an effective\n             method of contraception during the study and for at least 6 months after the\n             completion of bevacizumab therapy.\n\n          -  Patient or legally authorized representative must be able to understand and willing\n             to sign a written informed consent document.\n\n        Exclusion Criteria:\n\n          -  Patient must not have had myelosuppressive chemotherapy \u2264 3 weeks prior to entry onto\n             this study (or 6 weeks if prior nitrosourea).\n\n          -  Patient must not have had any anti-neoplastic biologic agent \u22647 days prior to entry\n             onto this study (or at least 3 half-lives for biologic agents with a long half-life).\n\n          -  Patient must not have received craniospinal radiotherapy or involved field\n             radiotherapy to the local tumor (and/or tumor designated as \"measurable\" for protocol\n             purposes) \u2264 24 weeks prior to study entry; focal radiation to areas of symptomatic\n             metastatic disease must not be given within 14 days of study entry.\n\n          -  Patient must not have received bevacizumab, or other anti-VEGF inhibitor in the last\n             3 months.\n\n          -  Patient must not require a major surgical procedure \u2264 21 days prior to beginning\n             therapy.\n\n          -  Patient must not require an intermediate surgical procedure \u226414 days prior to\n             beginning therapy.\n\n          -  Patient must not require a minor surgical procedure (i.e., Broviac line or infusaport\n             placement) \u2264 7 days prior to beginning therapy, and the wound must be healed prior to\n             initiation of therapy.\n\n          -  There should be no anticipation of need for major surgical procedures during the\n             course of the study.\n\n        Examples of Major, Intermediate, or Minor Surgical Procedures\n\n        Major Procedures       Intermediate Procedures Minor Procedures Organ resection\n        VP-shunt placement                 Incision drainage of\n                                                                superficial skin abscesses Bowel\n        wall anastomosis Stereotactic brain biopsy Punch biopsy of skin lesions Arteriovenous\n        grafts Paracentesis or thoracentesis Superficial skin wound suturing Exploratory\n        laparotomy  Bone marrow aspirate and/or biopsy Thoracotomy  Fine needle aspirations\n        Broviac line or infusaport placement\n\n        Note:  Lumbar punctures or placement of PICC lines are not considered minor procedures and\n        may occur at any time prior to or during therapy.\n\n          -  Patient must not have received any growth factors \u22647 days of entry onto this study.\n\n          -  Patient must not be taking NSAIDS, clopidogrel, dipyridamole, or aspirin therapy >81\n             mg/day.\n\n          -  Patient must not have a serious or non-healing wound, ulcer, or bone fracture.\n\n          -  Patient must not require sedation for imaging purposes.\n\n          -  Patient must not be receiving an investigational drug.\n\n          -  Patient must not be receiving any other anti-cancer agent.\n\n          -  Patient must not have an uncontrolled infection.\n\n          -  Patient must not have a history of abdominal fistula, gastrointestinal perforation or\n             intra-abdominal abscess \u2264 6 months prior to study entry.\n\n          -  Patient must not have a known bleeding diathesis or coagulopathy.\n\n          -  Patient must not have had significant vascular disease (e.g., Moya-Moya, aortic\n             aneurysm requiring surgical repair, deep venous or arterial thrombosis) \u2264 6 months\n             prior to study entry.\n\n          -  Patient must not have a known thrombophilic condition (i.e. protein S, protein C or\n             antithrombin III deficiency, Factor V Leiden, Factor II G20210A mutation,\n             homocysteinemia, or antiphospholipid antibody syndrome).  Testing is not required in\n             patients without a thrombophilic history.\n\n          -  Patient must not have evidence of a new CNS hemorrhage greater than 0.5cm on baseline\n             MRI obtained \u2264 14 days prior to study enrollment.\n\n          -  Patient must not have a history of stroke, myocardial infarction, transient ischemic\n             attack (TIA), severe or unstable angina, peripheral vascular disease, or grade II or\n             greater congestive heart failure \u2264 6 months prior to study entry.\n\n          -  Patient must not have serious and inadequately controlled cardiac arrhythmia\n\n          -  Patient must not be pregnant or breastfeeding.\n\n          -  Patient must not have a known hypersensitivity to Chinese hamster ovary cell products\n             or other recombinant human antibodies.\n\n          -  Patient must not be known to be HIV-positive on combination antiretroviral therapy\n             because of the potential for pharmacokinetic interactions with study therapy.  In\n             addition, these patients are at increased risk of lethal infections when treated with\n             marrow-suppressive therapy.\n\n          -  Patient must not have any contra-indications to MRI imaging including implanted\n             medical devices and metal objects which may be adversely affected by MRI imaging.\n             All subjects will be required to complete a standard MRI screening form prior to\n             imaging.\n\n        Inclusion of Female Patients and Minorities\n\n        Both male and female patients and members of all races and ethnic groups are eligible for\n        this trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999270", 
            "org_study_id": "201303069"
        }, 
        "intervention": [
            {
                "arm_group_label": "Irinotecan, Bevacizumab and FDOPA-PET/MRI imaging", 
                "description": "Irinotecan IV over 90 minutes on Days 1, 15, and 29 of each cycle (except Cycle 1, when it will be started on Day 29)\nNote: Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider.", 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Camptosar\u00ae", 
                    "CPT-11"
                ]
            }, 
            {
                "arm_group_label": "Irinotecan, Bevacizumab and FDOPA-PET/MRI imaging", 
                "description": "Bevacizumab will be given intravenously AFTER the irinotecan infusion is complete on Days 1, 15, and 29 of each cycle.  The first dose will be given over 90 minutes, but doses after that may be given over 30-60 minutes.", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin\u00ae"
            }, 
            {
                "arm_group_label": "Irinotecan, Bevacizumab and FDOPA-PET/MRI imaging", 
                "description": "FDOPA-PET/MRI imaging Baseline (before beginning Cycle 1 treatment) Cycle 1, Day 29 (before receiving your treatment with bevacizumab) and end of treatment or time of relapse", 
                "intervention_name": "FDOPA-PET/MRI imaging", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Irinotecan", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 15, 2014", 
        "link": {
            "description": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine", 
            "url": "http://www.siteman.wustl.edu"
        }, 
        "location": {
            "contact": {
                "email": "Gauvain_K@kids.wustl.edu", 
                "last_name": "Karen Gauvain, M.D.", 
                "phone": "314-286-2790"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": [
                {
                    "last_name": "Jonathan McConathy, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Joshua Rubin, M.D., Ph.D", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jeffrey Leonard, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Robert McKinstry, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Robert Hayashi, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Amy Barone, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors, A Feasibility Study", 
        "overall_contact": {
            "email": "Gauvain_K@kids.wustl.edu", 
            "last_name": "Karen Gauvain, M.D.", 
            "phone": "314-286-2790"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Karen Gauvain, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The imaging is evaluated: (a) the uptake of PET tracer FDOPA measured by average and maximal standardized uptake values (SUVs) as well as tumor to normal brain ratios; and (b) tumor volumes defined by MRI signal abnormality.", 
            "measure": "FDOPA-PET/MRI imaging", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999270"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}